Miniatura

Fitxers

jpm-13-01282-v2.pdf (1.8 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-08-21

Llicència de publicació

cc by (c) Ras Jiménez, Maria del Mar et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/207858

Soluble Transferrin Receptor as Iron Deficiency Biomarker: Impact on Exercise Capacity in Heart Failure Patients

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/jpm13081282

Resum

The soluble transferrin receptor (sTfR) is a marker of tissue iron status, which could indicate an increased iron demand at the tissue level. The impact of sTfR levels on functional capacity and quality of life (QoL) in non-anemic heart failure (HF) patients with otherwise normal systemic iron status has not been evaluated. We conducted an observational, prospective, cohort study of 1236 patients with chronic HF. We selected patients with normal hemoglobin levels and normal systemic iron status. Tissue iron deficiency (ID) was defined as levels of sTfR > 75th percentile (1.63 mg per L). The primary endpoints were the distance walked in the 6 min walking test (6MWT) and the overall summary score (OSS) of the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The final study cohort consisted of 215 patients. Overall QoL was significantly worse (51 +/- 27 vs. 39 +/- 20, p-value = 0.006, respectively), and the 6 MWT distance was significantly worse in patients with tissue ID when compared to patients without tissue ID (206 +/- 179 m vs. 314 +/- 155, p-value < 0.0001, respectively). Higher sTfR levels, indicating increased iron demand, were associated with a shorter distance in the 6 MWT (standardized beta = -0.249, p < 0.001) and a higher MLHFQ OSS (standardized fi = 0.183, p-value = 0.008). In this study, we show that in patients with normal systemic iron parameters, higher levels of sTfR are strongly associated with an impaired submaximal exercise capacity and with worse QoL.

Matèries

Dèficit de ferro, Marcadors bioquímics

Matèries (anglès)

Iron deficiency diseases, Biochemical markers

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

RAS JIMÉNEZ, Maria del mar, RAMOS POLO, Raúl, FRANCESCH MANZANO, Josep, CORBELLA SANTANO, Miriam, MORILLAS CLIMENT, Herminio, JOSE BAZÁN, Núria, JIMÉNEZ MARRERO, Santiago, GARCIMARTÍN CEREZO, Paloma, YUN VILADOMAT, Sergi, MOLINER BORJA, Pedro, TORRES CARDÚS, Blanca, VERDÚ ROTELLAR, José maria, DIEZ LOPEZ, Carles, GONZÁLEZ COSTELLO, José, GARCÍA ROMERO, Elena, FRUTOS SEMINARIO, Fernando de, TRIGUERO LLONCH, Laura, ENJUANES, Cristina, TAJES ORDUÑA, Marta, COMÍN COLET, Josep. Soluble Transferrin Receptor as Iron Deficiency Biomarker: Impact on Exercise Capacity in Heart Failure Patients. _Journal of Personalized Medicine_. 2023. Vol. 13, núm. 8. [consulta: 23 de gener de 2026]. ISSN: 2075-4426. [Disponible a: https://hdl.handle.net/2445/207858]

Exportar metadades

JSON - METS

Compartir registre